ライフサイエンスコーパス: hepatitis

1 cess alcohol consumption, obesity, and viral hepatitis.

2 ection, may result in clinically significant hepatitis.

3 ce ameliorates MHV-3-induced viral fulminant hepatitis.

4 ls worldwide and causes severely progressive hepatitis.

5 the treatment of various ailments including hepatitis.

6 e liver during resolution of immune-mediated hepatitis.

7 n typically causes self-limiting acute viral hepatitis.

8 eatures resembling those seen in human viral hepatitis.

9 r diseases, including tuberculosis and viral hepatitis.

10 ating in the pathogenesis of immune-mediated hepatitis.

11 on clinical pattern was a severe cholestatic hepatitis.

12 tocytes infected with the Japanese fulminant hepatitis 1 HCV strain as well as in biopsies of chronic

13 ry human hepatocytes with Japanese fulminant hepatitis-1 (JFH1) HCV cell culture system (HCVcc).

14 Remarkably, the hepatitis A virus (HAV) IRES requires eIF4E for its tran

15 udies show that some picornaviruses, notably hepatitis A virus (HAV; genus Hepatovirus) and some memb

16 erved as controls, with infections by either hepatitis A virus or hepatitis B virus (HBV), or a nonin

17 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 y

18 ore reactions at the injection site than the hepatitis A virus vaccine and saline.

19 re or present in sera from humans with acute hepatitis A.

20 ls were increased in patients with alcoholic hepatitis, a prototypic acute-on-chronic condition; and

21 Alcoholic hepatitis (AH) is the most severe form of alcoholic live

22 The diagnosis of alcoholic hepatitis (AH) often requires a transjugular liver biops

23 ain autoimmune diseases including autoimmune hepatitis (AIH).

24 on, has been associated with the severity of hepatitis and fibrosis progression during chronic hepati

25 LPS and D-galactosamine to induce fulminant hepatitis and MCC950 to specifically inhibit NLRP3; plas

26 rolongs survival times of patient with acute hepatitis associated with alcoholic liver disease (ALD).

27 o antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNAs are ac

28 Chronic hepatitis B (CHB) exhibits a variety of clinical outcome

29 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred in Chin

30 alog (NA) treatment in patients with chronic hepatitis B (CHB).

31 ir carriers to control infections with human hepatitis B (HBV) and C (HCV) viruses.

32 Chronic hepatitis B affects over 300 million people who are at r

33 V reactivation and graft loss from recurrent hepatitis B after liver transplantation in patients with

34 titis B recurrence for patients with chronic hepatitis B after liver transplantation.

35 Aflatoxin B1 (AFB1) and/or hepatitis B and C viruses are risk factors for human hep

36 cell leukemia virus, human papilloma virus, hepatitis B and C viruses, herpes simplex virus, norovir

37 The detection of minute amounts of hepatitis B antibodies was performed by plasmonically am

38 ld Health Organization resolved to eliminate hepatitis B as a public health threat by 2030.

39 ng severity, even in the setting of isolated hepatitis B core antibody, with or without accompanying

40 1 occurred in a patient known to be isolated hepatitis B core antibody-positive.

41 urface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive patients af

42 rus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV

43 %-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%-7

44 0.14-0.32) versus patients with antibody to hepatitis B core antigen only.

45 re likely to be HCV and antibody reacting to hepatitis B core antigen+, and less likely to have diabe

46 iral life cycle, with production of HBV DNA, hepatitis B e (HBe), core (HBc) and surface (HBs) antige

47 study was to identify miRNAs associated with hepatitis B e antigen (HBeAg) status and response to ant

48 Three hundred fifty-six hepatitis B e antigen (HBeAg)-seropositive, hepatitis B

49 Maternal hepatitis B e-antigen (HBeAg) and high viral load have b

50 Hepatitis B immune globulin (HBIG) has been an integral

51 Oral antiviral therapy alone without hepatitis B immune globulin is highly effective in preve

52 s treated with entecavir monotherapy without hepatitis B immune globulin.

53 , based on three national serosurvey data of hepatitis B in China, we propose an age- and time-depend

54 liver disease, and elimination strategies of hepatitis B in sub-Saharan Africa.

55 treating adolescents and adults with chronic hepatitis B infection.

56 long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with ent

57 strate the usefulness of this new transgenic hepatitis B model.

58 inically significant cardiovascular disease, hepatitis B or hepatitis C viral infection, and a known

59 ellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy with potent

60 study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who receive

61 ar 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with compens

62 Hepatitis B reactivation associated with immune-suppress

63 ar mechanisms, prevention, and management of hepatitis B reactivation.

64 antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatit

65 follow-up period, of which none were due to hepatitis B recurrence.

66 ity of persons currently treated for chronic hepatitis B require long-term or lifelong therapy.

67 Six patients had hepatitis B surface antibody (anti-HBs) titres above 10

68 hepatitis B surface antigen with or without hepatitis B surface antibody seroconversion, which is as

69 hepatitis B e antigen (HBeAg)-seropositive, hepatitis B surface antigen (HBsAg) carrier children, wh

70 Among 2334 RA patients who had available hepatitis B surface antigen (HBsAg) data, 123 patients p

71 , R21 particles are formed from a single CSP-hepatitis B surface antigen (HBsAg) fusion protein, and

72 A total of 42 hepatitis B surface antigen (HBsAg) positive, human immu

73 le HBV viral load, 7 had positive results on hepatitis B surface antigen (HBsAg) testing and had an u

74 Intradermal immunization of mice against hepatitis B surface antigen (HBsAg) using a novel real-t

75 The serum gradient of hepatitis B surface antigen (HBsAg) varies over time aft

76 Hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody t

77 tor high-risk children at 1 year of age with hepatitis B surface antigen and anti-hepatitis B to iden

78 HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with

79 Stratified by HBV coinfection status (hepatitis B surface antigen positive at baseline), we de

80 apy, the estimated overall seroprevalence of hepatitis B surface antigen remains high at 6.1% (95% un

81 onal cure characterized by sustained loss of hepatitis B surface antigen with or without hepatitis B

82 e gold sensor surface and post modified with hepatitis B surface antigen.

83 ge with hepatitis B surface antigen and anti-hepatitis B to identify those with chronic HBV infection

84 omes, ranging from spontaneous resolution of hepatitis B to severe adverse consequences, including th

85 a, and despite the introduction of universal hepatitis B vaccination and effective antiviral therapy,

86 oral and cell-mediated immunity responses to hepatitis B vaccination is still controversial.

87 es were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immuni

88 icle to present best practice statements for hepatitis B vaccination, screening, and linkage to care.

89 atients had missed opportunities to initiate hepatitis B vaccination.

90 lmette-Guerin (BCG) vaccine, Triple vaccine, Hepatitis B vaccine (HBV), Polio, Measles, Rubella, Mump

91 All participants received 3 doses of hepatitis B vaccine.

92 (FISH)-based assay for the detection of duck hepatitis B virus (DHBV) cccDNA and HBV nuclear DNA in e

93 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infe

94 Infections with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depe

95 tions and displays excellent potency against hepatitis B virus (HBV) and varicella-zoster virus (VZV)

96 transferase 1 (PRMT1) only modestly increase hepatitis B virus (HBV) biosynthesis.

97 been used to track the assembly of the T = 4 hepatitis B virus (HBV) capsid in real time.

98 ices to analyze in real time the assembly of Hepatitis B Virus (HBV) capsids below the pseudocritical

99 The hepatitis B virus (HBV) causes acute and chronic liver i

100 Hepatitis B virus (HBV) chronic infection affects up to

101 Hepatitis B virus (HBV) chronically infects 250 million

102 rus (HIV)-infected patients with and without hepatitis B virus (HBV) coinfection on antiretroviral th

103 HDV requires a hepatitis B virus (HBV) coinfection to provide HDV with

104 ified APOBEC deaminases as enzymes targeting hepatitis B virus (HBV) DNA in the nucleus thus affectin

105 nd 95%, 99%, 100%, and 100% had undetectable hepatitis B virus (HBV) DNA, respectively.

106 The management of hepatitis B virus (HBV) e antigen-positive viremic patie

107 Hepatitis B virus (HBV) encodes a multifunction reverse

108 Reactivation of hepatitis B virus (HBV) has been reported in hepatitis C

109 The basis for the persistence of hepatitis B virus (HBV) in hepatocytes, even in the pres

110 (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a melittin

111 Patients with resolved hepatitis B virus (HBV) infection who are treated for he

112 n patients with current or prior exposure to hepatitis B virus (HBV) infection.

113 th metabolic risk factors, for patients with hepatitis B virus (HBV) infection.

114 rcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

115 Hepatitis B virus (HBV) is a major global health concern

116 Hepatitis B virus (HBV) is endemic in sub-Saharan Africa

117 ), most cases of which are related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

118 Reports were published recently on hepatitis B virus (HBV) reactivation (HBV-R) in patients

119 Hepatitis B virus (HBV) reactivation in hepatitis B surf

120 an integral component of prophylaxis against hepatitis B virus (HBV) recurrence in liver transplantat

121 pies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) status.

122 REP 2139 clears circulating hepatitis B virus (HBV) surface antigen (HBsAg), enhanci

123 is in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD, and alcoholic liver dise

124 th infections by either hepatitis A virus or hepatitis B virus (HBV), or a noninfectious cause for th

125 Hepatitis B virus (HBV)-encoded X protein (HBx) plays a

126 disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer (NK) and

127 compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also signify

128 The study of hepatitis B virus and development of curative antivirals

129 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral

130 on-Pfizer monkey virus), two hepadnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an

131 pid, high yield and economical production of Hepatitis B Virus core (HBc) particles.

132 s associated with a similar modest change in hepatitis B virus core antigen polypeptide (HBcAg/p21) s

133 for novel biomarkers toward better defining hepatitis B virus cure should occur in parallel with dev

134 The hepatitis B virus deploys the hepatitis B virus X protei

135 New inhibitors of hepatitis B virus entry, replication, assembly, or secre

136 The management for occupational HIV or hepatitis B virus exposures includes postexposure prophy

137 FNalpha was confirmed in HEV gt1, but not in Hepatitis B Virus infected animals.

138 A cross-sectional analysis of prevalence of hepatitis B virus infection (HBV) among rural couples wa

139 For the discovery of hepatitis B virus integration sites from probe capture d

140 Chronic hepatitis B virus or hepatitis C co-infection was allowe

141 Hepatitis B virus reactivation, defined as an abrupt inc

142 yme as signal amplifier for determination of hepatitis B virus surface antigen (HBsAg).

143 in Egypt (1054 [84%] of 1251 patients), and hepatitis B virus was the leading cause in the other Afr

144 The hepatitis B virus deploys the hepatitis B virus X protein (HBx) as a suppressor of hos

145 tomegalovirus, human immunodeficiency virus, hepatitis B virus, and neonatal herpes simplex virus, fr

146 transfer of T cells engineered to express a hepatitis B virus-specific (HBV-specific) T cell recepto

147 Hepatitis B viruses (HBVs), which are enveloped viruses

148 persistent infection in people with chronic hepatitis B, leading to accelerated progression of liver

149 bility of tableted diagnostics for screening hepatitis B-positive patient samples.

150 good alternative to TDF for treating chronic hepatitis B.

151 curative antiviral therapies against chronic hepatitis B.

152 eseeable therapeutic developments in chronic hepatitis B.

153 phtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haemophilus influenzae type b) and pneu

154 m and long-term survival in severe alcoholic hepatitis based on baseline disease severity, extent of

155 reasing mortality in patients with alcoholic hepatitis but the underlying mechanisms are not well cha

156 Patients with chronic hepatitis C (HCV) infection have high prevalence of vita

157 mage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonheavy use i

158 Treatment was targeted against hepatitis C (ribavirin and interferon) in addition to im

159 ition has been a target for the treatment of hepatitis C and other diseases, but the generation of po

160 Chronic hepatitis B virus or hepatitis C co-infection was allowed.

161 Major developments in the management of hepatitis C have put elimination within reach, but sever

162 this Series paper, several issues related to hepatitis C in sub-Saharan Africa are addressed, includi

163 uture CHF events, particularly among HIV and hepatitis C infected people among whom cardiovascular di

164 itis and fibrosis progression during chronic hepatitis C infection, while contrasting results were re

165 terferon (IFN)-alpha treated chimpanzees and hepatitis C patients showed elevated APOBEC expression.

166 vational studies among compensated cirrhotic hepatitis C patients treated with interferon-containing

167 ses of acute symptomatic HEV infection after hepatitis C therapy in patients carrying anti-HEV immuno

168 Postpartum hepatitis C viral (HCV) load decline followed by spontan

169 icant cardiovascular disease, hepatitis B or hepatitis C viral infection, and a known bleeding disord

170 tocellular carcinoma and concomitant chronic hepatitis C viral infection.

171 Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in

172 Persons co-infected with hepatitis C virus (HCV) and HIV.

173 Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus

174 Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained

175 [BPA], and patient solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and

176 Hepatitis C virus (HCV) cure rates have been similar in

177 ey population affected by the global HIV and hepatitis C virus (HCV) epidemics.

178 cessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures.

179 r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HI

180 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of re

181 Hepatitis C virus (HCV) has dominated the field of hepat

182 miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and recruits

183 tly-acting antivirals has been advocated for Hepatitis C Virus (HCV) in people who inject drugs (PWID

184 The association between hepatitis C virus (HCV) infection and end-stage renal di

185 tive studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical

186 Whether chronic hepatitis C virus (HCV) infection decreases humoral and

187 acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high

188 ffective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected

189 Hepatitis C virus (HCV) infection is a major cause of li

190 Chronic hepatitis C virus (HCV) infection is associated with imp

191 efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined by measu

192 Hepatitis C virus (HCV) infection is prevalent in the re

193 Hepatitis C virus (HCV) infection is the most common chr

194 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-inf

195 lines now recommend that patients with acute hepatitis C virus (HCV) infection should be treated with

196 e the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, trea

197 ptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying me

198 ent of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an inc

199 patients with inherited blood disorders and hepatitis C virus (HCV) infection.

200 All patients with chronic hepatitis C virus (HCV) infections can and should be tre

201 Occult infection with hepatitis C virus (HCV) is defined as the presence of th

202 itious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of in

203 Hepatitis C virus (HCV) is one of the leading causes of

204 Chronic infection with hepatitis C virus (HCV) is one of the main causes of hep

205 nt pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was develope

206 BACKGROUND & AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component

207 enib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) statu

208 rotein synthesis to directly incorporate the hepatitis C virus (HCV) p7 protein into supported lipid

209 s an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic, and induction of broad

210 rd-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting

211 , exhibit potent inhibitory activity against hepatitis C virus (HCV) replication in genotype 1b Con 1

212 Hepatitis C virus (HCV) requires multiple receptors for

213 an electronic health record-based prompt on hepatitis C virus (HCV) screening rates in baby boomers

214 There is a need for hepatitis C virus (HCV) therapies with excellent efficac

215 for detection of cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD,

216 th decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hep

217 RNA (+RNA) viruses including human pathogens hepatitis C virus (HCV), Severe acute respiratory syndro

218 cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with

219 was cloned from T cells that expanded when a hepatitis C virus (HCV)-infected HLA-A2(-) individual re

220 k of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and the incide

221 Hepatitis C virus (HCV)-mediated chronic liver disease i

222 Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated

223 The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been s

224 IM-1 is important for efficient infection by hepatitis C virus (HCV).

225 l survival benefit for persons infected with hepatitis C virus (HCV).

226 mortality in patients with cirrhosis due to hepatitis C virus (HCV).

227 related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

228 A recombinant strain HCV1 (hepatitis C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) va

229 MC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naiv

230 rated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection.

231 called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such a

232 antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and t

233 Chronic hepatitis C virus infection is associated with significa

234 djusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug

235 ) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was asso

236 iral cytokine, are also less likely to clear hepatitis C virus infection.

237 stimulation during persistent infection with hepatitis C virus is associated with continuous activati

238 Hepatitis C virus is capable of establishing a lifelong

239 29382 young persons currently infected with hepatitis C virus lived >10 miles from a syringe service

240 s to those of the initiation complex for the hepatitis C virus polymerase.

241 ssion, all from an active IVDU donor who was hepatitis C virus seronegative at time of donation, but

242 There were 3 cases of unexpected hepatitis C virus transmission, all from an active IVDU

243 Extending hepatitis C virus treatment to patients in any fibrosis

244 Hepatitis C virus was the leading cause of hepatocellula

245 ople have been estimated to be infected with hepatitis C virus, and many more are at risk for infecti

246 SV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus 70, and variant Creutzfel

247 involved in the assembly and release of the hepatitis C virus, was determined from proteins expresse

248 enter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had

249 AA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (H

250 hepatitis B virus (HBV) has been reported in hepatitis C virus-infected individuals receiving direct-

251 the PITER cohort (representative of Italian hepatitis C virus-infected patients in care).

252 ir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-na

253 treatment policies in a real-life cohort of hepatitis C virus-infected policy 1, "universal," treat

254 Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethyla

255 be avoided in black patients with genotype 1 hepatitis C virus.

256 Hepatitis C viruses (HCV) encode a helicase enzyme that

257 ory and immunosuppressive medication against hepatitis C was the key reason for the good results in t

258 n some cases suggested to be associated with hepatitis C, although the evidence is very vague.

259 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and access to car

260 US West and South have been most impacted by hepatitis C.

261 further show that kinesin knockdown inhibits hepatitis-C virus replication in hepatocytes, likely bec

262 core antibody, with or without accompanying hepatitis can occur-though the occurrence of accompanyin

263 Hepatitis D virus (also known as hepatitis delta virus)

264 ron alfa-2a in patients with chronic HBV and hepatitis D virus (HDV) co-infection.

265 s with the human hepatitis B virus (HBV) and hepatitis D virus (HDV) depend on species-specific host

266 Hepatitis D virus (HDV) infection affects 15-20 million

267 The odds ratio for anti-hepatitis D virus detection among HBsAg-positive patient

268 TION: Findings suggest localised clusters of hepatitis D virus endemicity across sub-Saharan Africa.

269 a, where HBsAg prevalence is higher than 8%, hepatitis D virus might represent an important additive

270 y, only eight of which included detection of hepatitis D virus RNA among anti-hepatitis D virus serop

271 etection of hepatitis D virus RNA among anti-hepatitis D virus seropositive participants.

272 ) positive, human immunodeficiency virus and hepatitis D virus-negative patients with pretransplant H

273 We analyzed changes in hepatitis B virus and hepatitis delta virus (HDV) viral loads (VL) during teno

274 Hepatitis D virus (also known as hepatitis delta virus) can establish a persistent infect

275 gulated in CD8(+) T cells from patients with hepatitis delta.

276 Hepatitis E virus (HEV) infection is increasingly being

277 nsitivity to exogenous type I IFN.IMPORTANCE Hepatitis E virus (HEV) infection typically causes self-

278 Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections are limited and immun

279 Although hepatitis E virus (HEV) is regarded as a self-limiting i

280 Hepatitis E virus (HEV) is the most common cause of acut

281 Hepatitis E virus (HEV) recently has been shown to be an

282 Hepatitis E virus RNA levels also remained detectable in

283 23 patients with reactivation, 10 (43%) had hepatitis flare.

284 HEV) is the most common cause of acute viral hepatitis globally.

285 in addition to grade 3 thyroiditis, grade 3 hepatitis, grade 3 pneumonia, and grade 4 myocarditis).

286 y causes biliary atresia-like phenotypes and hepatitis in late organogenesis mouse embryos, but the m

287 2 was found to be responsible for aggravated hepatitis, indicating a novel role for TREM2 in the non-

288 roducts, in contrast, tend to cause an acute hepatitis-like injury.

289 HBV is a major cause of viral hepatitis, liver cirrhosis, and hepatocellular carcinoma

290 Data were analyzed from 14,841 viral hepatitis-negative adult participants in the third Natio

291 hat is absent in liver tissues from nonviral hepatitis or healthy subjects.

292 failing kidneys: OR 2.29; diabetes: OR 1.56; hepatitis: OR 1.30; depression: OR 1.47; hearing impairm

293 PBMs isolated from alcoholic hepatitis patients had high expression of SIRT1 and SIRT

294 of sorafenib on OS is dependent on patients' hepatitis status.

295 adhere to follow-up, and alert providers to hepatitis symptoms.

296 Overall, our data suggest murine hepatitis virus (MHV) ExoN activity is required for resi

297 ation and expression is altered due to mouse hepatitis virus (MHV)-A59 infection both in vivo and in

298 adnaviruses (hepatitis B virus and woodchuck hepatitis virus), and an intron-retaining transcript enc

299 though the occurrence of accompanying severe hepatitis was rare.

300 BV-infected HIS-HUHEP mice developed chronic hepatitis with 10-fold lower titers and antigen-specific